Hippocampal damage produces cognitive deficits similar to dementia and changes in emotional and motivated reactions similar to anxiolytic drugs. The gross electrical activity of the hippocampus contains a marked 'theta rhythm'. This is a relatively high voltage sinusoidal waveform, resulting from synchronous phasic firing of cells, variation in which correlates with behavioural state. Like the hippocampus, theta has been linked to both cognitive and emotional functions. Critically, it has recently been shown that restoration of theta-like rhythmicity can restore lost cognitive function. We review the effects of systemic administration of drugs on hippocampal theta elicited by stimulation of the reticular formation. We conclude that reductions in the frequency of reticularelicited theta provide what is currently the best in-vivo means of detecting antianxiety drugs. We also suggest that increases in the power of reticular-elicited theta could detect drugs useful in the treatment of disorders, such as dementia, that involve memory loss. We argue that these functionally distinct effects should be seen as indirect and that each results from a change in a single form of cognitive-emotional processing that particularly involves the hippocampus.
Introduction
In this paper, we review the effects of systemically administered drugs on hippocampal 'theta rhythm' that has been elicited by high-frequency, nonphasic, stimulation of systems afferent to the hippocampus. We focus in particular on drugs that can affect anxiety and cognition and will argue that their action on the ascending systems that elicit and control theta makes a significant contribution to their behavioural and clinical profile. From this, we suggest that reticular-elicited theta can be used to detect both anxiolytic and, perhaps also, procognitive drugs.
The hippocampus is well known for its involvement, together with other temporal lobe structures, in learning and the acquisition and recall of memories (O'Keefe and Nadel, 1978; Cohen and Eichenbaum, 1993) . From this, it seems likely that treatments that enhance hippocampal function could have at least some procognitive effects, reversing at least some of the symptoms of dementia. The hippocampus, however, has also been linked with the control of emotion (Papez, 1937; MacLean, 1949 MacLean, , 1990 . In particular, a very strong qualitative parallel has been drawn between the effects of anxiolytic drugs and hippocampal lesions (Gray and McNaughton, 2000) . This suggests that treatments that degrade hippocampal function could have at least some anxiolytic effects.
The parallel between hippocampal lesions and anxiolytic drug action extends to tests that are often viewed as assessing purely cognitive processes. Novel [acting via serotonin (5-hydroxytryptamine; 5-HT) neurotransmission] and classical [acting via g-aminobutyric acid (GABA) neurotransmission] anxiolytic drugs act through quite different primary neural mechanisms and have quite different side effects both in animal tests and in the clinic. Nonetheless, they have a common action on the Morris Water Maze Test (McNaughton and Morris, 1987, 1992) . This is the most common current test of hippocampal-mediated cognitive function and yet also appears to be a test of anxiolytic action, and is one of the few behavioural tests to have a linear dose-response curve with novel anxiolytic drugs (McNaughton and Morris, 1992) . This suggests that hippocampal function can range along a continuum between procognitive/ proanxiety and anticognitive/antianxiety actions. We will argue below that its functional position on this continuum can adjusted by the level (in terms of frequency or power) of the hippocampal theta rhythm; and that alteration of the ascending control of theta is the basis for some of the behavioural effects and clinical properties of the drugs we will review. We, however, will also argue, at the end of this paper, that procognitive and anxiolytic actions may be partially separable and, therefore, that obtaining one effect may not necessarily mean obtaining the other.
Hippocampal theta rhythm (theta activity) is an approximately sinusoidal electroencephalogram (EEG) activity that can be recorded at amplitudes as great as 1000 mV through gross electrodes placed almost anywhere in and around the hippocampal formation and entorhinal cortex.
[The name 'theta rhythm' derives from early experiments with anaesthetized or unmoving rabbits, cats and dogs in whom the frequency is in the human EEG theta band (4-7 Hz)]. Hippocampal theta, however, can range from 4 to even 14 Hz . Human frontal theta rhythm is substantially different from hippocampal theta (Burgess and Gruzelier, 1997) , despite some superficial parallels. Frontal or occipital theta may sometimes be linked to hippocampal theta. It has highly consistent behavioural correlates in rats (Vanderwolf, 1969) and its apparent simplicity and ease of recording have resulted in a voluminous literature (Bland, 1986; Winson, 1990; O'Keefe, 1993; Kirk, 1997; Vertes and Kocsis, 1997; Sainsbury, 1998; O'Keefe and Burgess, 1999; Buzsáki, 2002 Buzsáki, , 2005 Burgess and O'Keefe, 2005; Hasselmo, 2005; Lisman, 2005; Vertes, 2005) .
Theta has been suggested to be involved in sensorimotor integration (Bland and Oddie, 2002) but can also occur in the absence of movement when the animal is aroused (Sainsbury, 1998) . Many theories have postulated a contribution of theta activity to cognitive processing by the hippocampus (O'Keefe and Nadel, 1978; Fox and Ranck, 1979; Gray, 1982; Miller, 1991; Worden, 1992; Carpenter and Grossberg, 1993; Cohen and Eichenbaum, 1993; Gray and McNaughton, 2000) ; and, in particular, to the shared behavioural effects of anxiolytic drugs, septal lesions and hippocampal lesions (Gray, 1982; Gray and McNaughton, 2000) .
It has recently been shown that restoring theta-like rhythmicity, using an electrical circuit to bypass blocked inputs to the hippocampus, can restore learning in the Morris Water Maze Test (McNaughton et al., 2006) . This is one case where a procognitive effect of increased theta has been demonstrated -and gives some hope that elicitation of theta can provide a simple test of potential procognitive action. Equally, an anxiolytic benzodiazepine injected directly into the supramammillary nucleus, one of the nuclei that controls theta frequency McNaughton, 1991, 1993; Kocsis and Vertes, 1997; Kocsis and Kaminski, 2006) , has similar effects on both theta frequency and behaviour to those it has when injected systemically (Woodnorth and McNaughton, 2002) . This suggests that elicitation of theta can provide a simple test of potential anxiolytic action. A good reason exists, then, to see the capacity of a drug to increase or decrease theta rhythm as being likely to have major functional implications and potential therapeutic applications.
Theta rhythm is easily recorded in rats, rabbits, cats, dogs and other small mammals. Its existence in primates has been controversial. As with the rat data reviewed in the remainder of this paper, theta, however, can also be elicited in the human hippocampus by hypothalamic stimulation (Sano et al., 1970) and clear theta activity, with a pharmacological resemblance to rodent theta, has been demonstrated in urethane-anaesthetized monkeys (Stewart and Fox, 1991) . A number of recent studies have reported theta from human hippocampus in analogues of tasks in which rats produce theta (O'Keefe and Burgess, 1999; Tesche and Karhu, 2000; Cantero et al., 2003; Ekstrom et al., 2005) . The data obtained in rodents that we review below, therefore, are likely to reflect neural changes that have functional implications for human clinical conditions.
Elicitation of theta
It has been known for some time that high frequency trains of stimulation of the midbrain reticular formation can elicit hippocampal theta rhythm (Green and Arduini, 1954; Sailer and Stumpf, 1957; Stumpf, 1965) . Increasing levels of stimulation produce a linear increase in the frequency of theta both in anaesthetized (Sailer and Stumpf, 1957) and in free-moving rats (Fig. 1) .
It is important to note that, unless the stimulation activates an adjacent motor pathway, elicited theta is not normally accompanied by movement, with reticular placements. Movement can affect results with drugs that interact with the cholinergic system (see below) and, for that reason, can produce apparent differences between free-moving and anaesthetized preparations. Pharmacologically speaking, there appear to be two main 'types' of theta in unanaesthetized animals. The theta accompanying movement is insensitive to muscarinic antagonists, whereas theta occurring during immobility (spontaneous or drug-induced) is blocked by them (Vanderwolf, 1988) . Serotonin depletion by itself does not have obvious effects on movement-related theta. The combination of 5-HT depletion and muscarinic antagonists, however, results in a total abolition of theta whether the animal is moving or not (Vanderwolf and Baker, 1986; Vanderwolf, 1987) . This was interpreted by Vanderwolf as showing that movement-related theta has a combination of underlying cholinergic and serotonergic components, either of which permits theta to occur. Later studies have failed to demonstrate a role for 5-HT in the active promotion of theta. Averaging techniques and spectral analysis, however, have confirmed the presence of a weak atropine-resistant theta even under urethane anaesthesia elicited by high intensity brainstem stimulation (Kocsis and Li, 2004; Li et al., 2007) . This shows that nonmovement theta has at least some underlying noncholinergic component. Cholinergic-supported and serotonergic-supported theta can, therefore, occur either separately or concurrently depending on the state of the animal (Leung, 1985) .
The entire range of frequencies of theta can be elicited, unchanged, in the presence of anticholinergic drugs (McNaughton and Sedgwick, 1978) ; but at all frequencies the occurrence or not of theta appeared to depend on whether, at the time of stimulation, the animal was moving, however slightly (McNaughton, unpublished observations) . Similarly, in a figure reporting the effects of atropine on theta in freely moving animals (Vanderwolf, 1975, Fig. 5) , such theta as occurs after atropine is essentially identical to that which occurs before atropine but, in the absence of movement, theta is not elicited. Some have linked nonmovement (cholinergic) theta with lower frequencies and movement theta with higher frequencies. This, however, is due to the behavioural conditions under which such theta is typically obtained in the laboratory. With appropriate stimuli, nonmovement theta can reach frequencies as high as 12 Hz (Sainsbury RS, personal communication, Fig. 1 in Sainsbury and Montoya, 1984) .
These results have been interpreted (Gray and McNaughton, 2000) as evidence for multiple 'gates' that permit theta to occur but do not affect its frequency. Different gates can permit (release) theta, separately or jointly. Which specific gates are operative would depend on the behavioural state of the animal. The presence of these gating systems is important for our understanding of the different effects that can be obtained with elicitation of theta from different ascending systems.
Stimulation of ascending cholinergic systems can elicit clear theta; but increasing levels of stimulation have a very modest effect on its frequency (Kirk, 1993) . Injections of local anaesthetic into a pathway that arises in the pedunculopontine tegmentum do not alter frequency of theta at all -producing a simple on/off effect of the injections (McNaughton et al., 1997) . By contrast, similar injections into the ascending reticular pathway produce major changes in frequency (Kirk, 1993; Kirk and McNaughton, 1993) . This suggests that stimulation of the pedunculopontine tegmentum activates two separate pathways: a presumed cholinergic one which has a permissive effect on the production of theta; and a noncholinergic one, which travels by some different route and produces a modest activation of a frequencycontrol system, gated by the cholinergic system. Likewise, electrical stimulation within the median raphe (Graeff et al., 1980; Peck and Vanderwolf, 1991) elicits both immobility and a theta rhythm which shows only a moderate increase with stimulus intensity. This elicitation of theta is unaffected by the administration of serotonergic drugs, and is blocked by anticholinergic drugs. It is therefore likely to involve cholinergic neurones (Lewis and Shute, 1967) rather than the serotonergic (Dahlström and Fuxe, 1965) cells. In fact, recent findings indicate that some brainstem 5-HT neurons exert a tonic inhibitory regulation of hippocampal theta activity. Thus, in anaesthetized rats, inhibition of activity of median raphe neurons evokes theta oscillation of septal neurons and hippocampal EEG (Kinney et al., 1995; Varga et al., 2002) ; and inhibition of 5-HT neurons by the selective 5-HT1A receptor agonist 8-hydroxy-2-dipropylaminotetralin induces hippocampal theta activity not only in anaesthetized rats Kinney et al., 1996) but also in freely moving cats, as well (Marrosu et al., 1996) . Furthermore, 5-HT2c receptor agonists inhibit, whereas 5-HT2c receptor antagonists induce or augment, septal and hippocampal theta oscillation in anaesthetized (Hajos et al., 2003b) and freely moving rat (Kantor et al., 2005; Kocsis and Hajos, unpublished) . In line with these observations, enhanced hippocampal norepinephrine, but not 5-HT neurotransmission, induces theta (and gamma) oscillatory activity of the septohippocampal system in anaesthetized rats (Hajos et al., 2003a) .
The key point to note, in relation to the data that we will review below, is that if clear drug effects are to be obtained on theta frequency, care must be taken to stimulate the pathways that normally elicit theta with a strong relationship between stimulation intensity and theta frequency; and to avoid pathways that can modulate or gate theta but that do not normally contribute to frequency. The focus of the review is on elicited theta, also, because with spontaneously occurring theta, apparent effects of drugs on theta could be indirect effects of the drugs on behaviour rather than an effect on theta generating mechanisms themselves.
The effects of drugs on the elicitation of theta have been tested both in nonanaesthetized and anaesthetized animals. The anaesthetic most commonly used in these cases is urethane. Barbiturates (see below) have very strong effects on theta frequency and essentially eliminate theta at anaesthetic doses. They have not, therefore, been used as anaesthetics in the study of the effects of drugs on elicited theta.
Urethane and ether both appear to generally produce (relative to the nonanaesthetized state) a reduction in the frequency of theta elicited with hypothalamic or midbrain reticular stimulation (Kramis et al., 1975a) . Theta, however, is unchanged at some stimulation sites. Overall, this means that we must be prepared for significant differences in the effects of other drugs when these are tested in awake as opposed to anaesthetized animals.
Theta frequency reduction and anxiolysis
In this section, we review the effects of drugs that have a primary use as anxiolytics in the clinic. We distinguish anxiolytic action, in this sense, from antipanic, antiphobic, antiobsessive/compulsive actions. These actions are neurally distinct (see below) but the symptoms affected tend to co-occur in the different disorders (panic disorder, simple phobia, obsessive-compulsive disorder, social anxiety disorder etc.) that are conflated as 'anxiety disorders' by Diagnostic and statistical manual of mental disorders. We argue that all currently known anxiolytic drugs, defined in this narrow way, reduce the frequency of reticular-elicited theta; and that they achieve this common effect through quite distinct pharmacological, and proximal neural, mechanisms. Both theoretically (Gray and McNaughton, 2000) and given the apparently Stein et al., 1992 Stein et al., , 2004 Westenberg, 1999; Gray and McNaughton, 2000; McNaughton, 2002; Rickels and Rynn, 2002; Stevens and Pollack, 2005 . Different patterns of response in the table can be attributed to the variation in receptor occupancy or interaction of particular drugs in different parts of the brain. No drug or drug class produces a specific limited effect (despite the omission of side effects from the table) but the variation in relative effectiveness across the different aspects of disorders of fear and anxiety argues for distinct neural control of each effect. 0, no effect; -, reduction; -, extensive reduction; + , increase; ( ), small or discrepant effects. BDZ 1 : early benzodiazepines, for example, chlordiazepoxide (Librium) and diazepam (Valium) administered at typical antianxiety doses. Other sedative antianxiety drugs (barbiturates, meprobamate) have similar effects; BDZ 2 , later high potency benzodiazepines, for example alprazolam (Xanax). The antipanic effect is achieved at higher doses and this has also been reported with equivalent high doses for BDZ 1 (Noyes et al., 1996) ; BUS, buspirone (BuSpar) and related 5-HT1A agonists; CMI, clomipramine (Anafranil); MAOI, monoamine oxidase inhibitors, for example phenelzine (Nardil); SSRI, selective serotonin reuptake inhibitors, for example fluoxetine (Prozac); TRI, imipramine and related tricyclic antidepressants, but excluding clomipramine.
indirect and delayed clinical action of these drugs, it should be possible to find anxiolytic drugs with a quite different mode of action -we will return to this issue in our conclusions.
What is an anxiolytic drug?
The term 'anxiety' is often used clinically to include a wide spectrum of disorders of defensive reactions. A good reason exists to distinguish fear and anxiety functionally (Blanchard and Blanchard, 1990a, b) , pharmacologically (Gray, 1977; Blanchard et al., 1997) and neurally (Gray and McNaughton, 2000) . By contrast, the term 'anxiolytic', when used as a clinical class identifier (when contrasted with, e.g. antidepressant, antipanic and antiobsessive agents), is used in a fairly restricted fashion. It applies to two main classes of drug that can treat a group of anxiety disorders, particularly generalized anxiety, but are not generally effective in treating specific phobia, panic, obsession or depression and the like (Table 1) . Anxiolytic action is obtained, in addition to other actions, by various other classes of drug (e.g. antidepressants, Table 1 ). A key issue to be addressed below is how far specific anxiolytic action, across many different classes of compound, can be linked to the capacity to change hippocampal theta.
The two main classes of anxiolytic drugs are 'classical anxiolytics' that act at GABA A receptors (see below), and novel anxiolytics that act through 5-HT 1A receptors (see below). Buspirone was the first novel anxiolytic to be marketed. It is a partial agonist at 5-HT 1A receptors and, although it has antidepressant action, does not affect panic and has been used mainly to treat anxiety.
Tricyclic drugs and specific 5-HT reuptake inhibitors block reuptake of 5-HT and so increase its levels in the synaptic cleft. They are normally termed 'antidepressant' drugs, but have similar actions to buspirone on anxiety and, in addition, are effective in treating panic. An important point (as all of the novel, serotonergic, anxiolytics have some antidepressant action) is that the anxiolytic action of these drugs appears to be independent of their antidepressant action (Kahn et al., 1986; Nemeroff, 2003) .
Monoamine oxidase inhibitors are like tricyclic drugs in that they increase levels of 5-HT (and noradrenaline) in the synaptic cleft and in that they are classed as antidepressants. As the name implies, they, however, block the breakdown of these monoamines by monoamine oxidase and do not affect reuptake. They may, as a result, have a somewhat different clinical profile from tricyclic drugs. Phenelzine has been reported to be particularly effective in the treatment of atypical depression, which presents with concurrent anxiety symptoms, panic attacks or phobia, and in the treatment of the symptomatically similar 'endogenous anxiety' (Sheehan et al., 1981; Liebowitz et al., 1984; Quitkin et al., 1988 Quitkin et al., , 1990 ). This appears to be different from conventional anxiolytic action as, in the case of Sheehan's study, essentially all the patients had been treated for years with conventional anxiolytic drugs without obtaining relief (Sheehan et al., 1981) . Thus, although they do reduce anxious symptoms in what appears to be a specialized form of depression, monoamine oxidase inhibitors appear to have a different type of anxiolytic action to that seen with the novel and classical anxiolyticsand have not been reported to be useful in treating generalized anxiety.
Clonidine is an a-adrenoceptor agonist which has been prescribed for the relief of anxiety associated with panic disorders or with morphine withdrawal (Gold et al., 1978; Hoehn-Saric et al., 1981; Redmond, 1981; Charney et al., 1983) . It also has anxiolytic effects in animal models of anxiety (Insel et al., 1984) and so can potentially be classified as an anxiolytic.
Baclofen is a GABA B -agonist that has been reported to reduce clinical ratings of anxiety and the incidence of panic attacks (Breslow et al., 1989) .
All classes of anxiolytic reduce theta frequency
All known classes of drugs that are clinically effective in treating generalized anxiety disorder (barbiturates, benzodiazepines, 5-HT 1A receptor agonists, selective serotonin reuptake inhibitors) decrease the frequency of reticular-elicited theta. Critically, drugs that are antipsychotic or sedative but not anxiolytic (haloperidol, chlorpromazine) do not have this effect.
Imipramine, is particularly interesting in this context. It is effective in treating generalized anxiety disorder and does so independently of its antidepressant action (Kahn et al., 1986 ). It appears to increase 5-HT levels particularly effectively at sites with 5-HT 1A receptors given its substitution capacity in drug discrimination studies (Barrett and Zhang, 1991) . The fact that a significant part of its 5-HT transmission facilitation is via 5-HT 1A receptors has been argued to be the basis of its clinical anxiolytic action (Gardner, 1988) . As discussed later, the effect of 5-HT1 A -acting drugs on reticular elicited theta is blocked by a 5-HT 1A receptor blocker but not by a benzodiazepine receptor blocker; and vice versa for the effects of benzodiazepines. This double dissociation means that these different classes of anxiolytic are acting on quite distinct proximal neural pathways that then converge on the hippocampal production of theta as a final common neural path that generates their common effects.
5-HT in the postsynaptic cleft -but through a quite different mechanism and so, potentially, a quite different balance in the types of 5-HT receptors affected. It has not been reported to be effective in generalized anxiety disorder and, as noted above, is effective in anxious depression that is refractory to conventional anxiolytic drugs. It has no immediate action on reticular-elicited theta (see below) but does have an effect if administered chronically. Its effects on reticular-elicited theta, therefore, predict a capacity to affect anxiety in the same way as conventional anxiolytics, but at a longer delay. Its effects on anxious (atypical) depression, however, clearly operate via a different mechanism and it is not clear whether this action is technically anxiolytic or whether the change in symptoms of anxiety is secondary to a change in depression.
The acute effects of the monoamine oxidase inhibitor and antidepressant, phenelzine and the effects of antipsychotic drugs are totally unlike those of conventional anxiolytics (McNaughton et al., 1986; Zhu and McNaughton, 1994a) . The immediate effects of the anxiolytics on theta frequency are more likely, then, to be related to effects on generalized anxiety than on schizophrenia, endogenous depression or atypical depression.
There are three drugs that are not commonly used as anxiolytics that do reduce the frequency of reticularelicited theta: baclofen, clonidine and ethanol. In the case of baclofen and clonidine, as we noted above, it can be argued that there is evidence for some clinical anxiolytic action -even if this is not the primary action of the drug and may be masked by other (e.g. antipanic) actions. Ethanol is in a sense the oldest anxiolytic drug. As we will see below it acts, like other classical anxiolytic drugs, via the GABA A receptors, but of course has a variety of additional actions.
The extent to which the reticular-elicitation test lacks false positives and false negatives is in strong contrast to the bulk of current animal models used in anxiolytic detection. It seems likely that it involves a critical neural pathway for the action of the drugs. A number of features of the pharmacology of anxiolytic effects on reticularelicited theta, however, are present that are important for interpreting this correlation with clinical action.
First is the fact that the effects of both classical and novel anxiolytics on reticular elicited theta are immediate, and long term administration does not change these effects greatly (Zhu and McNaughton, 1991a, b) . All classes of anxiolytic drugs, however, require at least a week's administration to achieve their full clinical effect and show similar temporal changes when assessed with clinical anxiety scales (Wheatley, 1990) . (The muscle relaxant side effects of the classical anxiolytics and the negative hedonic effects of buspirone, both of which show tolerance, tend to mask the similar temporal trends in their core anxiolytic action on the central nervous system.) The effects of the drugs on the hippocampus, then, are not directly on anxiety itself but (like the much broader effects of hippocampal damage) are more akin to an anterograde amnesia for threats -blocking the formation of new anxious cognitions but, for a while, leaving those that were formed earlier intact. Here, we see anxiolytic action as, to some extent, the inverse of the procognitive action discussed below.
Second is the role of corticosteroids in the neural and behavioural effects of anxiolytic drugs. As we note below, buspirone appears slightly different from classical anxiolytics in that it does not change the slope of the function relating stimulation intensity to frequency. Buspirone is known to release corticosterone (de Boer et al., 1990) . This is in contrast to classical anxiolytics, which block the release of corticosterone. When chlordiazepoxide is administered together with corticosterone, similar effects on theta to those of buspirone are produced .
It is probably this release of corticosterone which gives buspirone its U-shaped dose-response curve in many acute-administration animal tests, and probably also in the clinic. This release of corticosterone can be presumed to have an anxiolytic blocking or anxiogenic effect (Johnston and File, 1988) . The development of tolerance in the capacity to release corticosterone explains in part both the superficially slower onset of buspirone's clinical effects compared with benzodiazepines and the withdrawal syndrome produced by the latter (Zhu and McNaughton, 1995b; McNaughton et al., 1996) .
Final evidence for a specific link between reduced theta frequency and anxiolytic action comes from the fact that the GABA A drugs and 5-HT1 A drugs such as buspirone, imipramine and fluoxetine have nothing in common in the clinic other than anxiolytic action. The serotonergic drugs are not anticonvulsant, hypnotic, muscle relaxant or addictive (Riblet et al., 1982) -indeed, to some extent, they have the opposite effects. The common effect of all these anxiolytic drugs on theta frequency, and their linear dose-response curves, contrasts with the general failure of animal behaviour models to detect all classes of clinically effective anxiolytic.
Classical anxiolytics and the gamma-aminobutyric acid receptor
As we noted briefly above, classical anxiolytics all act via a GABA A receptor -but they do so via different binding sites. This is important both for the identification of the GABA A receptor as their common target and for important variations in their clinical action. The role of this receptor in the control of reticular-elicited theta has received some analysis that we will review below.
Compounds acting on the benzodiazepine-binding site can enhance GABA-mediated Cl -current (positive allosteric modulators, such as anxiolytic benzodiazepines), reduce the effect of GABA (negative allosteric modulators, also called inverse agonists, such as FG-7142), or have no effect on the actions of GABA. In this latter case, they act to prevent other ligands from binding at the benzodiazepine-binding site. Drugs such as Ro 15-1788 (flumazenil) are thus benzodiazepine, but not GABA, antagonists (for reviews see Haefely et al., 1993; Sieghart, 2006) . Opposite effects of positive and negative allosteric modulators of GABA A receptors on hippocampal theta have been demonstrated in anaesthetized rats (Hajos et al., 2004a; Ujfalussy et al., 2007) .
The gamma-aminobutyric acid type A receptor allosteric modulators and theta Activity of GABA A receptors can be modulated by endogenous neurosteroids (Hosie et al., 2006) , as well as drugs acting at different allosteric sites of the pentameric receptors (Rudolph and Mohler, 2004) . As pure GABA A receptor-positive allosteric modulators do not directly affect the ion channel, but rather augment or diminish any ongoing GABAergic neurotransmission, they are the most desirable targets for pharmacotherapy. Known positive allosteric modulators include the benzodiazepines, barbiturates, ethanol, halothane and enflurane -of which only the benzodiazepines have essentially pure allosteric action. The different classes of drug act at a number of distinct binding locations at GABA A receptors. Barbiturates, ethanol, halothane and enflurane all have the capacity, at higher doses to directly open the chloride channel in the absence of GABA -rendering them dangerous at doses much above the normal clinical range. The benzodiazepines, however, act only by allosteric modulation of the interaction of GABA with its binding site and therefore have much less action at high doses, making them much less toxic. Owing to this, they have immense clinical importance and their binding site and mode of action have been studied most intensively (Sieghart, 2006) . Most of the benzodiazepines currently in clinical practice are nonselective at different a-subunit-containing GABA A receptors, although there is a significant effort in drug discovery to identify subunit-specific modulators of GABA A receptors (Atack, 2005) .
The frequency of reticular-elicited theta rhythm is decreased, and the slope of the intensity-frequency function (Fig. 1) is decreased, by all drugs that are positive allosteric modulators of GABA A receptors, including ethanol (Coop et al., 1990) , barbiturates such as hexobarbitone (Stumpf, 1965) , amylobarbitone (McNaughton and Sedgwick, 1978; McNaughton et al., 1986; Coop et al., 1992) , pentobarbitone (Kramis et al., 1975b) and benzodiazepines such as chlordiazepoxide (McNaughton et al., 1986; McNaughton and Coop, 1991; Zhu and McNaughton, 1991a, b; Coop et al., 1992) , diazepam (McNaughton et al., 1986; Siok and Hajos, unpublished observations) and alprazolam (McNaughton et al., 1986) . Chlordiazepoxide has a linear dose-response curve in the range 0.1-20 mg/kg, intraperitoneally , and ethanol has a linear dose-response curve in the range 1.7-3.1 g/kg, intraperitoneally (Coop et al., 1990) . This is consistent with the doses of both drugs required to affect anxiety-related behaviour in rats (Gray, 1977) .
The effect of chlordiazepoxide is retained even when administered three times/day for 45 days. This links its reticular effect to anxiolytic action rather than muscle relaxant, euphoriant and other side effects which show tolerance. Its effect is also potentiated rather than blocked by the nonspecific 5-HT1 A antagonist, pindolol (Zhu and McNaughton, 1991a) as is the effect of the barbiturate, amylobarbitone (Coop et al., 1992) . (Pindolol blocks the effects of serotonergic drugs, see below.) The effect of chlordiazepoxide is not blocked by administration of the 5-HT synthesis inhibitor p-chloro-phenylalanine, nor by b-blockers (Zhu and McNaughton, 1994b) . This implies that anxiolytic drugs that act via GABA neurotransmission affect theta frequency through quite different mechanisms than those that act via 5-HT neurotransmission. The effects of chlordiazepoxide are, as expected, blocked by the benzodiazepine binding site antagonist, Ro 15-1788 (Bonetti et al., 1988; Coop et al., 1992) .
The effects of ethanol have been challenged with the partial benzodiazepine inverse agonist Ro 15-4513 which appears to be a selective ethanol antagonist (Suzdak et al., 1986) . Interestingly, this antagonized the effect of ethanol on the overall frequency of reticular-elicited theta but did not antagonize its effects on the slope of the function relating stimulation to frequency (Fig. 1) . This is consistent with the separation of these variables by the 5-HT1 A partial agonist, buspirone (see Novel anxiolytics and serotonergic mechanisms) and by administration of corticosterone (see Theta modulation by anxiolytics).
Direct agonists and antagonists at gamma-aminobutyric acid type A and gamma-aminobutyric acid type B receptors
Both GABA A and GABA B direct receptor agonists have been tested with reticular elicitation of theta. The GABA A agonist, muscimol, produced effects that were surprising in two ways. First, at very low doses it produced an increase in the frequency of theta. This is the opposite effect to that of the GABA A -positive allosteric modulators and other drugs that increase chloride flux. As we saw in the previous section, these consistently decrease the frequency of theta. Second, muscimol had an inverted U-shaped dose-response curve (over a very wide range of doses, 0.00001-1.0 mg/kg, intraperitoneally), so that at the highest dose tested it had essentially no effect .
At present, there is no evidence that muscimol has a clinical anxiolytic action. In animal tests of anxiolytic action, it produces mixed results (Rodgers and Dalvi, 1997) but appears to have a narrow window of anxiolyticlike action in the range 1-3 mg/kg with a general disruption of behaviour occurring at 3 mg/kg and above (Dalvi and Rodgers, 1996; Rodgers and Dalvi, 1997) . This possible anxiolytic action would be consistent with the frequency-decreasing trend in the data on reticularelicited theta if the observed dose-response curve were extrapolated beyond 1 mg/kg. On this view, low doses of muscimol would bind to high-affinity GABA A receptors that lacked benzodiazepine sites and could act to increase the frequency of theta. At higher doses, muscimol would also bind to a low-affinity receptor containing benzodiazepine sites and so produce a countervailing reduction in frequency and the observed inverted U dose-response curve.
The GABA B agonist, baclofen, produced no effect at 1 mg/kg, and a dose-related decrease in frequency (and of the slope of the stimulation-frequency function) at 3 and 9 mg/kg -which are high, essentially sedative, doses and are, interestingly, also the doses required to produce impairments in hippocampal-dependent spatial learning (McNamara and Skelton, 1996) . At 27 mg/kg, baclofen eliminated theta . The mechanisms underlying the effects of baclofen on hippocampal activity are unclear, but it is known that GABA B receptors are located at axon terminals capable of modulating release of various neurotransmitters (Bettler and Tiao, 2006) . The effect of baclofen was blocked by the nonspecific 5-HT 1A antagonist, pindolol (Coop et al., 1992) , and so may be mediated, secondarily, by the systems on which the serotonergic drugs act, as discussed below.
Novel anxiolytics and serotonergic mechanisms
Distinct, dorsal and median raphe, serotonergic systems are present in the brain, with potentially different functions. The serotonergic drugs with clear anxiolytic actions, and with effects on theta, appear to act via 5-HT 1A receptors (see below) and these receptors can either directly affect other neurons (with agonists acting like 5-HT) or can act directly on autoreceptors (with agonists suppressing the firing of serotonergic neurons and so, for nonserotonergic neurons, effectively acting as serotonergic antagonists). Before considering the role of the 5-HT 1A drugs in elicited theta, we will first, therefore, consider the role of 5-HT itself.
As we noted earlier, 5-HT depletion, by itself, does not have obvious effects on the occurrence of theta. The frequency of theta elicited by reticular stimulation is also unaffected by blockade of 5-HT synthesis with p-chlorophenyl-alanine (McNaughton and Sedgwick, 1978; Zhu and McNaughton, 1994b) . If 5-HT depletion, however, is combined with a muscarinic antagonist, this eliminates theta (Vanderwolf and Baker, 1986; Vanderwolf, 1987) . Serotonin may thus provide a subsidiary 'gating' mechanism to acetylcholine. Stimulation of the median raphe 5-HT system, however, replaces theta with desynchrony (Macadar et al., 1974; Vertes, 1981; Peck and Vanderwolf, 1991) , although blockade of this system produces an increase in immobility-related, atropine-sensitive theta activity (Maru et al., 1979; Kinney et al., 1995; Vertes and Kocsis, 1997, p. 913 ; see also Vinogradova, 1995, p. 564) . In cats, where serotonergically gated theta is not commonly observed, systemic administration of 5-HT 1A agonists releases theta through an action on autoreceptors, presumably in the median raphe (Marrosu et al., 1996) . Critically, the 5-HT 1A receptors on which buspirone and related drugs act to alter the frequency of theta (see below) cannot be on the targets of any tonically active serotonergic cells (autoreceptors or otherwise) as serotonergic depletion does not affect theta frequency.
The overall frequency of elicited theta but, unlike with GABAergic drugs, not the slope of the stimulationfrequency function, is reduced by administration of the 5-HT 1A partial agonist, buspirone, which has a threshold dose of approximately 0.5 mg/kg, intraperitoneally, and a dose-related effect up to at least 40 mg/kg . Frequency is also reduced (Coop et al., 1992) by the 5-HT1 A full agonist 8-hydroxy-di-n-propylamino tetralin. The effect of buspirone on frequency is unchanged after administration, three times per day for 45 days (Zhu and McNaughton, 1991a) . The lack of effect of buspirone on the slope of the function is consistent with the separation of these variables that we discussed in relation to ethanol (see above) and, with the effects of long-term administration (see 'The Gammaaminobutyric acid type A receptor allosteric modulators and theta').
Consistent with the effect of buspirone, imipramine (which blocks reuptake of both 5-HT and noradrenaline) produces a decrease in reticular-elicited theta frequency when administered acutely, with a threshold in the region of 3 mg/kg, intraperitoneally and dose-related effects up to 30 mg/kg (Zhu and McNaughton, 1991b) . As with buspirone this acute effect does not change with repeated administration but there is an increase in the baseline frequency of theta over repeated testing on which the acute decrease is superimposed (Zhu and McNaughton, 1991b) . The acute effect of imipramine has been replicated with the specific 5-HT reuptake inhibitor, fluxoetine, at doses between 5 and 20 mg/kg, intraperitoneally (Munn and McNaughton, submitted for publication).
The effects of buspirone, 8-hydroxy-di-n-propylamino tetralin and imipramine were all blocked by the nonselective 5-HT 1A receptor antagonist pindolol Coop et al., 1992; Zhu and McNaughton, 1994b) . In the case of buspirone, this effect was shown not to depend on the separate action that pindolol has on adrenergic b-receptors. The effect of imipramine, but not buspirone, was blocked by the 5-HT synthesis inhibitor p-chloro-phenyl-alanine (Zhu and McNaughton, 1994b) . Thus imipramine appears to act by increasing the levels of 5-HT at sites containing 5-HT 1A receptors.
Clonidine is an a-adrenoceptor agonist. This also reduced frequency and the effect was blocked by pindolol, suggesting a secondary action on 5-HT 1A -mediated systems (Coop et al., 1992) .
The effects of buspirone are not blocked by administration of the benzodiazepine antagonist Ro 15-1788 (Coop et al., 1992) , even after long-term administration (Zhu and McNaughton, 1991a) . These results suggest that a wide range of drugs reduce theta frequency by acting directly, or indirectly, on 5-HT 1A presynaptic or postsynaptic receptors that are not autoreceptors -and do so independently of benzodiazepine receptors. (As we noted above, the effects of benzodiazepines are not blocked by pindolol.)
Neither the 5-HT 2 antagonist methysergide, nor the 5-HT 3 antagonist GR38032F (ondansetron) affected reticular-elicited theta and, more significantly, neither they, nor the D 2 antagonist haloperidol, blocked the effects of buspirone .
In partial contrast to the effects of imipramine, phenelzine (0.6-18.0 mg/kg, intraperitoneal), a monoamine oxidase inhibitor that reduces the break down of dopamine, noradrenaline and 5-HT, had no effect on reticular-elicited theta administered acutely. It, however, eventually reduced theta frequency when administered every day for 35 days at 2 mg/kg/day (Zhu and McNaughton, 1995a) . In the long-term case, it also produced the increase in baseline frequency seen with long-term administration of imipramine.
Adrenergic mechanisms
The frequency of theta elicited by reticular stimulation is unaffected by the blockade of noradrenaline and dopamine synthesis with a-methly-p-tyrosine (McNaughton and Sedgwick, 1978) . Consistent with this, haloperidol and chlorpromazine, drugs with dopamine antagonist action, were also without effect (McNaughton et al., 1986 ).
As noted when considering serotonergic drugs, acute imipramine (which blocks reuptake of both 5-HT and noradrenaline) produces a decrease in reticular-elicited theta frequency (Zhu and McNaughton, 1991b) . The acute effect of imipramine could involve noradrenaline. Its effect, however, is blocked by the 5-HT1 A antagonist pindolol and the 5-HT synthesis inhibitor p-chlorophenyl-alanine (Zhu and McNaughton, 1994b) ; and its effect has been replicated with the specific 5-HT reuptake inhibitor, fluoxetine (Munn and McNaughton, submitted for publication). This suggests a role for a serotonergic mechanism in this action of imipramine. On the other hand, we have recently demonstrated that reboxetine, a selective reuptake inhibitor of norepine phrine (Hajos et al., 2004b ) also reduced brainstem stimulation-induced hippocampal theta oscillation (Li, Kocsis and Hajos, unpublished observation, Fig. 2) . Interestingly, reboxetine also reduced the threshold necessary to induce theta oscillation, in line with previous findings demonstrating its theta-inducing effects (Hajos et al., 2003a) and unanaesthetized rats . It is possible, then, that 5-HT and noradrenaline can have similar, and perhaps synergistic, effects on reticular-elicited theta.
Blockade of monoamine oxidase has no acute effects but produces a decrease in frequency with longer-term administration (Zhu and McNaughton, 1995a) , most likely through the same neural systems as imipramine.
The D 2 agonist apomorphine is the only drug so far to have had an effect on the slope of the stimulationfrequency function (Fig. 1) without also reducing frequency . Together with buspirone it shows a double dissociation of these two parameters.
Enhanced theta power: a sign of procognitive action?
In the previous section we made a substantial case that a reduction in the frequency of elicited-theta rhythm predicts anxiolytic action. As we noted at the beginning of the paper, injection of anxiolytic drugs into the medial supramammillary area reduce theta and anxiolytic-sensitive behaviour concurrently and to the same extent, in both cases, as systemic injections (Woodnorth and McNaughton, 2002) . Furthermore, the behavioural profile of anxiolytic drugs can be viewed as being like that of diffuse, or in some other way moderate, hippocampal damage (Gray, 1977; McNaughton, 1983, 2000) . These data are all then evidence for some degree of hippocampal involvement in the control of anxiety.
The hippocampus, however, is generally seen as being more involved in cognitive functions than in anxietyand in this section we ask how far elicited theta may provide a test bed for procognitive drugs. That is, we ask whether increases in theta can predict improvement in memory function, in contrast to decrease in theta predicting anxiolytic action. This apposition is not unreasonable as high doses of anxiolytic drugs produce some degree of retrograde amnesia (Coull et al., 1999) and both classical and novel anxiolytic drugs impair acquisition in the Morris Water Maze Test (McNaughton and Morris, 1987, 1992) . Indeed the Water Maze is one of the few behavioural tests that has a linear dose-response curve with buspirone (McNaughton and Morris, 1992) . It should, however, be noted that the apposition is not unidimensional. Anxiolytics reduce theta frequency with only minor changes in power; drugs that manipulate memory affect power with little or no change in frequency.
Neuronal network oscillations, reflecting neuronal synchronization have been positively linked to various cognitive processes, including memory formation (Buzsaki and Draguhn, 2004; Axmacher et al., 2006) . Hippocampal theta rhythm has also been associated with learning and memory for over three decades (Berry and Thompson, 1978; Winson, 1978; Berry and Seager, 2001) ; and a correlation between learning and hippocampal theta has been demonstrated in experimental animals (Buzsaki, 2002 (Buzsaki, , 2005 Jones and Wilson, 2005) and humans (Caplan et al., 2003; Sammer et al., 2006) . Hippocampal theta has been suggested to be a 'neutral tetanizer' contributing to long-term synaptic modulations, such as long-term potentiation (LTP) in vivo (Winson, 1990; Vertes, 2005) . Critically, a direct functional contribution of theta frequency oscillation has been shown in rats in which theta had been blocked: restoration of theta rhythmicity also restored learning (McNaughton et al., 2006) . Thus a reason exists to suppose that drugs that improve theta could improve cognitive function and we will consider, below, the small amount of evidence for increases in theta being produced by procognitive drugs of different classes of drugs: mainly cholinergic and histaminergic. Before doing so, we will consider the evidence for the converse: that anticholinergic drugs block elicited theta. This is important because, not only are anticholinergic drugs amnestic, but disruption of the cholinergic system is one important feature of dementing disorders. We will briefly note similar data for the involvement of N-methyl-D-aspartate (NMDA) receptors in both memory and the control of theta.
Cholinergic antagonists
In freely moving rats, provided they are immobile at the time of stimulation, injections of muscarinic antagonists have the same effects as in anaesthetized rats, eliminating theta when this is elicited from a wide variety of sites (Kramis et al., 1975a; Robinson and Vanderwolf, 1978; Kramis and Vanderwolf, 1980) . When theta is elicited by stimulation of the subnucleus compactus of the pedunculopontine tegmental area this, however, appears resistant to atropine even in the absence of voluntary movement (Robinson and Vanderwolf, 1978) . As we noted in the section on theta induction, if the animal is engaging in any movement during stimulation then the elicitation of theta is not blocked by anticholinergic drugs and, indeed, seems completely unaffected in either frequency or amplitude (McNaughton and Sedgwick, 1978) .
Involvement of muscarinic receptors in hippocampal theta generation can also be demonstrated clearly by recording brainstem stimulation-induced hippocampal theta oscillation in anaesthetized rats. Thus, amplitude of elicited theta oscillation can be greatly reduced (up to 70-80%) by the muscarinic receptor antagonists atropine or scopolamine, whereas lower frequency theta oscillations are abolished by these antagonists (Kinney et al., 1999; Kocsis and Li, 2004; Siok et al., 2006; Li et al., 2007) .
N-methyl-D-aspartate receptor antagonists
NMDA receptors mediate LTP -a likely basis of longterm learning and memory (Abraham, 2003) . Alteration in their function impacts various cognitive mechanisms, including LTP-dependent memory formation (Castellano et al., 2001) . For example, the NMDA receptor antagonist, dizocilpine (MK-801), impairs performance in a hippocampal-dependent spatial learning task (Butelman, 1989) . Furthermore, blockade of NMDA receptors decreases both the frequency and power of hippocampal theta activity in freely moving rats (Pitkänen et al., 1995) ; and, in particular, dizocilpine reduces elicited theta at the same dose as it produces a deficit in cognitive performance (Kinney et al., 1999) . This suggests that elicited theta could be increased by procognitive drugs acting via the NMDA receptor, but none appear to have been tested so far.
It should be noted, here, that in animal tests, blockade of NMDA receptors has been linked to anxiolytic-like action (Dunn et al., 1989; Guimaraes et al., 1991; Xie and Commissaris, 1992; Anthony and Nevins, 1993; Xie et al., 1995; Sajdyk and Shekhar, 1997; Adamec et al., 1998; Gatch et al., 1999) . This is consistent with the changes in theta frequency observed with NMDA receptor blockade in freely-moving rats (Pitkänen et al., 1995) .
Cholinergic agonists
As would be expected from the theta-blocking effects of the amnestic anticholinergic drugs, the acetylcholinesterase inhibitor, donepezil, a clinically proven memory improving drug, significantly enhances the amplitude of reticular elicited theta oscillations, and can reverse the theta-disruptive effects of scopolamine (Kinney et al., 1999; Siok and Hajos, unpublished observations) . Increase in power of stimulation-induced hippocampal theta has also been observed with other preclinically identified procognitive compounds such as piracetam and apamin. Interestingly, the theta-enhancing effects of donepezil, as well as piracetam and apamin are attenuated by scopolamine, therefore a common cholinergic mechanism by which these drugs enhance theta activity and improve cognition has been suggested (Kinney et al., 1999) .
In addition to acetylcholinesterase inhibitors and agonists of muscarinic receptors (Power et al., 2003; Hasselmo, 2006) , agonists of nicotinic cholinergic receptors have been considered as procognitive drugs (Buccafusco et al., 2005; Levin et al., 2006; Mansvelder et al., 2006) . For example, cognitive enhancing actions of a7 nAChR agonists have been observed both preclinically in various animal models (Levin et al., 2006; Wishka et al., 2006; Pichat et al., 2007) and in clinical studies (Kitagawa et al., 2003; Olincy et al., 2006) .
The contribution of nicotinic acetylcholine receptors to brainstem stimulation-induced theta has not been extensively explored. In the septohippocampal formation, a7 nicotinic receptors (a7 nAChRs), however, are expressed by neurons well positioned to modulate hippocampal theta oscillation, such as GABAergic interneurons in the hippocampus, by both GABAergic and cholinergic septal neurons (Ji and Dani, 2000; Henderson et al., 2005; Thinschmidt et al., 2005) . Consistent with this, the recently developed selective a7 nAChR agonist PNU-282987 significantly enhances the power of hippocampal theta elicited by brainstem reticular formation stimulation (Siok et al., 2006) . In addition, amphetamineinduced hippocampal theta oscillation is enhanced by PNU-282987 in rats (Hajos et al., 2005a) .
Potential modulation of elicited hippocampal theta by other subtype-specific nicotinic receptors has not been evaluated. Mutation of a4 nicotinic receptors in mice, however, has been shown to result in hypersensitivity to nicotine, and to nicotine-induced hippocampal theta oscillation (Fonck et al., 2005) . It would, therefore, be of particular interest to determine whether a4 nicotinic receptors modulate physiological or stimulation-induced theta oscillations in the hippocampus.
One final point to note is that PNU-282987 can augment elicited theta frequency above 6.5 Hz (Figs 2 and 3 , from Siok et al., 2005) . Thus, although endogenous muscarinic systems appear to promote the power but not the frequency of theta (see above), exogenous (and possibly endogenous) nicotinic systems may play some role in the control of frequency.
Histaminergic mechanisms
Despite considerable effort to identify procognitive mechanisms and compounds, only a few drugs have been proven clinically effective until now. One of the potential targets in mnemonic drug discovery is the histamine system. Direct or indirect activation of the histamine pathway has been proposed to impact cognitive functions positively (Bacciottini et al., 2001) , including antagonists or inverse agonists at histamine3 (H3) receptors (Passani et al., 2004; Esbenshade et al., 2006) .
Histaminergic neurons project to the medial septum/diagonal band of Broca (MS/DB) and presumably innervate both cholinergic and GABAergic septal neurons (Panula et al., 1989) . Although, in the rat brain-slice preparation, it has been shown that histamine excites septal GABAergic and cholinergic neurons (Xu et al., 2004) , the role of histamine and various histamine receptors in hippocampal function or hippocampal network oscillations has not been fully investigated. In-vivo recordings from the hippocampal CA1 region of freely moving rats have revealed that high-frequency oscillations (200-Hz ripples) are markedly enhanced after injection of the H1-antagonists, indicating a tonic regulation of hippocampal activity by the histaminergic system (Knoche et al., 2003) . In addition, systemic administration of H3 receptor antagonists enhances spontaneously occurring theta power in chloral hydrate anaesthetized rats (Hajos et al., 2005b) .
Involvement of H3 receptors in reticular-induced theta has been recently demonstrated. Systemic administration of H3 antagonists (ciproxifen and thioperamide) enhanced power without influencing theta frequency (Hajos et al., 2005b) . In contrast, application of H3 antagonists directly to the MS/DB via microdialysis does not modulate stimulated theta activity, indicating that the theta-modulating effects of H3 antagonists are not mediated directly via MS/DB neurons. These results are in line with preclinical behavioural studies indicating cognitive enhancing effects of H3 receptor antagonists (Passani et al., 2004) , and suggest that the procognitive effects of H3 antagonists could be mediated, at least in part, by modulation of hippocampal oscillatory activity.
Conclusion
The role of theta in anxiety and memory
The data we have reviewed make a strong case for seeing reductions in the frequency of reticular-elicited theta as providing a good in-vivo means of detecting antianxiety drugs, independent of their mode of action. We also have indications that increases in the power of reticularelicited theta could detect drugs useful in the treatment of disorders, such as dementia, that involve memory loss. At first blush, it might seem we are suggesting that increases and decreases in theta have qualitatively distinct actions from each other. We might also be seen to be suggesting that the occurrence of theta represents anxiety and memory formation. Here we argue against both of these apparent implications.
First, let us make clear that the presence of theta does not mean that it is fulfilling a function. In rats, the 
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The effect of increasing stimulation intensity on theta frequency after administration of the selective a7 nicotinic receptor agonist PNU-282987 (1 mg/kg, intravenous, n = 5, left panels), and its vehicle (n = 5; right panels). PNU-282987 caused a subtle, but significant (P < 0.05) increase in frequency (bottom left panel) only at frequencies greater than 6.5 Hz (from Siok et al., 2005) . strongest correlate of hippocampal theta frequency is speed of movement. Yet elimination of theta, or even complete removal of the hippocampus, has no obvious effect on simple movement, per se. Theta must then be seen as providing an input to the hippocampus which is only critical if the hippocampus is, at that point in time, required to perform a function. Consistent with this, the relation of theta to movement is not strong in other species and, as we go from rabbit to rat to cat to monkey to human the overall occurrence of theta appears to drop. Theta rhythm has been observed to occur clearly but briefly in monkeys as a result of an unprogrammed failure of delivery of reward, when criterion performance is reached on no-go trials of a go/no-go problem (Crowne et al., 1972) . It has been suggested that 'in the monkey . . . the theta rhythm (is) virtually impossible to see, excepting under conditions likely to produce extreme emotional reactions' (Green, 1960 cited by Crowne et al., 1972) and we would argue that, in more encephalized species, the occurrence of theta in the hippocampus, relative to rodents, has been largely restricted to those situations where it is important for function. Even in rodents, the cholinergic 'gating' of theta (see 'Elicitation of theta') shows that the nuclei controlling theta continue to encode reticular system activation as theta frequency even when production of theta activity is prevented in the hippocampus itself.
Second, let us consider the relation of theta, and drug action, to arousal. Theta is modulated by noradrenaline, 5-HT and histamine (systems involved in arousal and motor activation); and is elicited by stimulation of what used to be called the ascending reticular activating system. Indeed, it has in the past been referred to as the arousal reaction of the hippocampus (Brucke et al., 1959) . The data we have reviewed are consistent with a more general involvement of theta in the effects of arousal. High arousal is a problem for those with anxiety; although low arousal can be a problem in cognitive tasks. To date, there has, however, been no evidence linking theta to functions that are not mediated by the hippocampusand the latter is certainly not involved, generally, in arousal. Similarly, there is good reason to see anxiolytic action as a combination of changes in behavioural inhibition (mediated by the hippocampus and so influenced by theta) and autonomic arousal mediated by the amygdala (Gray and McNaughton, 2000) . Thus, although anxiolytic drugs and procognitive drugs may produce opposite shifts along a continuum of hippocampal-mediated function they have additional quite distinct effects in other parts of the nervous system that may contribute selectively to anxiolytic and procognitive action, respectively. Third, let us make clear that the hippocampal function (or functions) that we presume requires theta is neither directly related to anxiety nor directly related to memory.
When considering the effects of antianxiety drugs we noted that their effect on theta was immediate and unchanging with repeated administration; whereas their clinical effect is cumulative and delayed -when assessed by clinical anxiety scales (Wheatley, 1990) . We argued that this clinical action can be viewed somewhat like the anterograde amnesia associated with hippocampal dysfunction. Equally, that same anterograde amnesia, so-called, is neither a loss of memory (as older memories are intact after hippocampal lesion) nor a loss of the capacity to form memories (as there are clear cases where certain classes of item can be learned and it is their unlearning that shows a deficit). Rather, hippocampal dysfunction appears to be the result of a failure to suppress incorrect alternatives (McNaughton and Wickens, 2003) , both in memorial and nonmemorial tasks under conditions where there is a high level of competition (see below).
It is clear that decreases and increases in theta can alter hippocampal function in an essentially anxiolytic and an essentially procognitive direction, respectively. This suggests that, on average, the presence or absence of theta is not necessarily a good or a bad thing. Changes in theta can adjust the system to a requirement for greater or lesser hippocampal output depending on the circumstances. If this were not the case, theta would be continuous and unchanging; the elaborate machinery for its control would not have evolved (and would not have been progressively more restricted in more encephalized species); and endogenous compounds that can alter its frequency and amplitude (as evidenced by the presence of multiple types of receptors for this) would also not have evolved.
The role of theta in hippocampal function
We have said that, in our view, the hippocampal processing controlled by theta activity is neither directly related to anxiety nor directly related to memory but impacts on both. How can two such apparently disparate classes of process be impacted by a single function executed by the hippocampus? One explanation is provided by the theory that the hippocampal formation is a key node of a behavioural inhibition system (for an extensive exposition of the ideas summarized below, see Gray and McNaughton, 2000 and its appendices available on the Oxford University Press website).
The core of the theory is that when two or more goal representations in the brain are approximately equally activated, the motor system is faced with a conflict that it cannot easily resolve: it cannot achieve both goals at once; and it cannot easily choose one over the other as they are equally activated. This conflict is detected by the hippocampus, which then produces output that inhibits the production of the competing behaviours (hence 'behavioural inhibition system'); and, critically, sends output back to the conflicting goal representations that increases the valence of affectively negative aspects of their memory representations. As detailed by Gray and McNaughton, this affectively negative feedback is increased progressively by a recursive process that repeatedly circulates information between the goal representations and the hippocampus. Theta activity quantizes this recursive processing to reduce the possibility of information from one cycle of processing interfering with the next cycle. The frequency of theta is, for this reason, tuned to the round trip time between the hippocampus and at least its cortical targets (Miller, 1991) . On this view, theta is necessary but not sufficient for a high level of hippocampal output and that output affects cognitive processing in an affectively negative way: increasing negative bias and so suppressing alternatives that have negative valence. Thus, with a high level of hippocampal output there will be higher gain in affectively negative associations leading to suppression of the goal with the greater negative associations (and so, in memory tasks, reduced interference) and with a low level there will be low gain in affectively negative associations leading to release of suppression (and so, in approach-avoidance conflicts ultimately reduced anxiety). Thus, although theta can be viewed as having a critical effect on cognitive processing (and so both action and memory), it does so via primarily affective means. It is concerned, then, with cognitive-emotional interaction (Pan and McNaughton, 2004) .
So far we have argued for an essentially unitary function of the hippocampus and so of alterations in theta. We need to add two caveats.
First, the older 'emotion' and newer 'memory' theories of hippocampal function have been essentially amalgamated, recently, in the suggestion that the hippocampus may be divided into distinct septal and temporal parts, associated with memorial and emotional/motivational processing, respectively (Moser et al., 1993; Moser and Moser, 1998; Bannerman et al., 2004; Trivedi and Coover, 2004; Cenquizca and Swanson, 2006) . Thus theta (and the repetitive 'slices' of which the hippocampus is made) would perform essentially the same computational operations throughout -but the operations performed would focus more on cognitive differences between goals (food to the left versus food to the right) or more on motivational differences (approach food versus avoid shock) depending on whether they were occurring in the septal or temporal portions of the hippocampus. The anxiolytic and procognitive drugs might, then, have distinct actions by acting primarily at different hippocampal locations. The clear anticognitive effects of high doses of the anxiolytic drugs suggest that such a separation is far from total, if it exists at all. Second, anxiolytics reduce theta frequency but, by and large, procognitive drugs alter theta power -most likely via changes in the extent to which the occurrence of theta is 'gated in'. Part of the functional difference in their actions, then, could be due to the qualitatively different ways in which (or the different task phases during which) they alter theta. In particular, cholinergic activation would be expected to have its greatest effects when the animal is stationary while frequency reduction would be expected to have its greatest effects when the animal is moving. Certainly, an anxiolytic and an anticholinergic drug, at doses that produce equivalent disruption in the rate of water maze learning, disrupt learning through substantially different patterns of dysfunctional behaviour (McNaughton and Morris, 1987) . Thus, anxiolytic and anticognitive drugs may appear to produce a similar level of cognitive disruption through somewhat different cognitive mechanisms.
Can anxiolytic and anticognitive actions be separated?
As we have already discussed, muscarinic receptor antagonists and GABA A receptor-positive allosteric modulator benzodiazepines have a similar capacity to reduce hippocampal theta activity and cognitive functions. But, although benzodiazepines are anxiolytic, muscarinic receptor antagonists are not. Therefore, it can be argued that either different neural circuits or distinct changes in cellular activities within the same circuits are involved in the actions of the different classes of drug and so have different effects on functions associated with hippocampal theta. In particular, we argued above that the drugs might affect behaviour through different task phases. It is not clear that anxiolytic action can be separated from anticognitive action. A strong possibility, however, exists that procognitive effects indicated by increases in theta activity can be produced in the absence of concurrent anxiety as a side effect.
A very important point, here, is that both theoretically (Gray and McNaughton, 2000) and practically there should be anxiolytic drugs that have a quite distinct mode of action from those currently used. Even conventional anxiolytic drugs (i.e. those without antidepressant action) act directly on the amygdala and indirectly (via theta) on the hippocampus to have their effects. Changes in theta, then, cannot be the whole story. From the practical point of view, both GABA and 5-HT anxiolytics have a delayed clinical effect on anxiety proper (Wheatley, 1990 ) -with the delay masked for the GABA drugs by initial muscle relaxant and euphoriant effects that show rapid tolerance. It follows that there could be drugs that can have immediate effects on anxiety proper. Two possible reasons exist, why at present, reticular elicitation of theta has no clear false-negative compounds. First, anxiety may be so cognitively mediated that time will always be required for new learning to alter cognitions. Second, it is possible that direct drug effects on, say, central arousal systems normally show tolerance and so have not given rise to drugs that are therapeutically useful with longer treatment durations.
Overall, then, we believe the data we have reviewed suggest that reticular-elicited theta is an excellent screen for anxiolytic action -capable of detecting drugs with novel modes of action -and a potential screen for procognitive action. The contribution of changes in theta to these end effects should, however, be seen as indirect. It appears to occur through a change in cognitiveemotional processing that particularly involves the hippocampus and then impacts later on other structures that directly involve anxiety and memory.
